It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DVAX’s FA Score shows that 1 FA rating(s) are green whileELAN’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ELAN’s TA Score has 7 bullish TA indicator(s).
DVAX (@Pharmaceuticals: Other) experienced а +0.22% price change this week, while ELAN (@Pharmaceuticals: Other) price change was +7.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.00%. For the same industry, the average monthly price growth was +4.86%, and the average quarterly price growth was -4.70%.
DVAX is expected to report earnings on Feb 27, 2024.
ELAN is expected to report earnings on Feb 21, 2024.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
|DVAX||ELAN||DVAX / ELAN|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
2 days ago81%
2 days ago90%
2 days ago80%
2 days ago69%
2 days ago83%
3 days ago59%
2 days ago80%
7 days ago62%
2 days ago82%
2 days ago62%
2 days ago80%
2 days ago59%
4 days ago83%
2 days ago63%
2 days ago84%
2 days ago86%
2 days ago77%
2 days ago57%
|ETFs / NAME||Price $||Chg $||Chg %|
|ProShares Russell US Dividend Grwr ETF|
|FT Cboe Vest US Equity Deep Bffr ETF Mar|
|Vanguard Russell 1000 Value ETF|
|Breakwave Dry Bulk Shipping ETF|
|Nuveen Municipal Credit Opportunities Fund|
A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.
A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with ZTS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then ZTS could also see price increases.